SIETES :: 93212 citas

Resultados de la búsqueda por DISLIPEMIAS REFINAR BÚSQUEDA

21.

Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 2015;8:189-99. [Ref.ID 99700]

22.

Downs JR, O'Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S.. Ann Intern Med 2015;163:291-7. [Ref.ID 99500]

23.

Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol 2015;80:179-81. [Ref.ID 99474]

24.

Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann Intern Med 2015;163:64-5. [Ref.ID 99337]

25.

Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry US, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ. Effect of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [Ref.ID 99336]

26.

Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom?. N Engl J Med 2015;372:1564-5. [Ref.ID 99059]

27.

Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]

28.

Anónimo. Lomitapide. Prescrire 2015;35:168-71. [Ref.ID 98923]

29.

Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]

30.

Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]

31.

Miedema MD, López FL, Blaha MJ, Virani SS, Coresh J, Ballantyne CM, Folsom AR. Eligibility for statin therapy according to new cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US cohort: the atherosclerosis risk in communities study cohort. JAMA Intern Med 2015;175:138-40. [Ref.ID 98727]

32.

Anónimo. Los lípidos como factor de riesgo cardiovascular: tratamiento farmacológico. Infac: Información Farmacoterapéutica de la Comarca 2014;22:37-43. [Ref.ID 98319]

33.

Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Slein EA, for the DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19. [Ref.ID 97589]

34.

Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy. A systematic review. Ann Intern Med 2014;160:468-76. [Ref.ID 97523]

35.

Albert L, González-Clemente JM. Prevención cardiovascular primaria con estatinas en la diabetes mellitus tipo 2: ¿es hora de cambiar de estrategia?. Med Clin (Barc) 2014;142:358-9. [Ref.ID 97378]

36.

Tonelli M, Wanner Ch, for the Kidney disease: improving global outcomes lipid guideline development work group members. Lipid management in chronick Kidney disease: synopsis of the Kidney disease: improving global outcomes 2013 clinical practice guideline. Ann Intern Med 2014;160:182-93. [Ref.ID 97317]

37.

Guallar E, Laine C. Controversy over clinical guidelines: listen to the evidence, not the noise. Ann Intern Med 2014;160:361-2. [Ref.ID 97294]

38.

Martin SS, Blumenthal RS. Concepts and controversies: the 2013 American college of cardiology/American heart association risk assessment and cholesterol treatment guidelines. Ann Intern Med 2014;160:356-8. [Ref.ID 97293]

39.

Downs J, Good C. New cholesterol guidelines: has Godot finally arrived?. Ann Intern Med 2014;160:354-5. [Ref.ID 97292]

40.

Krumholz HM. Target cardiovascular risk rather than cholesterol concrentration. BMJ 2013;347:7. [Ref.ID 96710]